Grand Theravac Life Sciences (nanjing) Co., Ltd.
Clinical trials sponsored by Grand Theravac Life Sciences (nanjing) Co., Ltd., explained in plain language.
-
New shot shows promise in fight against chronic hepatitis b
Disease control OngoingThis study tests an experimental injection called TVAX-008 in 80 adults with chronic hepatitis B who are already taking antiviral pills. Half receive the injection and half receive a placebo for 24 weeks, then some may continue with TVAX-008 for another 24 weeks. The goal is to s…
Phase: PHASE2 • Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 17:21 UTC
-
New shot aims to tame hepatitis b in patients with low viral activity
Disease control OngoingThis early-phase study tests a new injection called TVAX-008 in 20 adults with chronic hepatitis B who have very low virus levels or have lost the virus surface marker but not yet developed protective antibodies. The goal is to see if the injection can safely boost the body's imm…
Phase: EARLY_PHASE1 • Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New shot aims to clear hepatitis b virus in Long-Term patients
Disease control OngoingThis study tests an experimental injection called TVAX-008 in 48 adults with chronic hepatitis B (a long-term liver infection). The goal is to see if it can safely clear the hepatitis B surface antigen (HBsAg) from the blood, which would indicate strong virus control. Participant…
Phase: PHASE2 • Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:18 UTC